Clinical Trials Logo

Recurrent Medulloblastoma clinical trials

View clinical trials related to Recurrent Medulloblastoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05096481 Not yet recruiting - High Grade Glioma Clinical Trials

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

Start date: April 15, 2024
Phase: Phase 2
Study type: Interventional

This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) as well as recurrent medulloblastoma (MB). PEP-CMV is a vaccine mixture of a peptide referred to as Component A. Component A is a synthetic long peptide (SLP) of 26 amino acid residues from human pp65. The SLPs encode multiple potential class I, class II, and antibody epitopes across several haplotypes. Component A will be administered as a stable water:oil emulsion in Montanide ISA 51. Funding Source - FDA OOPD